{"transactions":[{"id":905782,"issuer":{"id":7338,"kind":"organization","name":"CervoMed Inc."},"owners":[{"id":66563,"kind":"person","name":"Winton Matthew","position":1,"cik":"0001971400","reported_name":"Winton Matthew","relationship":{"officer":true,"officer_title":"Chief Commercial and Business"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-13T22:02:27.000Z","date":"2026-02-11","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the award will vest in 36 equal (or as near equal as possible) monthly installments on the last calendar day of each month over a 36-month period commencing February 28, 2026."}],"balance_after":30000,"derivative":{"exercise_price":4.8,"expiration_date":"2036-02-11","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001437749-26-004168","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1053691/000143774926004168/rdgdoc.xml","form_type":"4"}},{"id":994379,"issuer":{"id":7338,"kind":"organization","name":"CervoMed Inc."},"owners":[{"id":66563,"kind":"person","name":"Winton Matthew","position":1,"cik":"0001971400","reported_name":"Winton Matthew","relationship":{"officer":true,"officer_title":"Chief Commercial and Business"}}],"security":"Common Stock","published_at":"2025-11-19T12:46:15.000Z","date":"2025-11-18","kind":"purchase","planned":false,"acquired":true,"shares":1500,"price":7.95,"value":11925.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares purchased in open-market transactions."}],"balance_after":15000,"source":{"system":"sec-edgar","filing":"0001437749-25-035655","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1053691/000143774925035655/rdgdoc.xml","form_type":"4"}},{"id":994378,"issuer":{"id":7338,"kind":"organization","name":"CervoMed Inc."},"owners":[{"id":66563,"kind":"person","name":"Winton Matthew","position":1,"cik":"0001971400","reported_name":"Winton Matthew","relationship":{"officer":true,"officer_title":"Chief Commercial and Business"}}],"security":"Common Stock","published_at":"2025-11-19T12:46:15.000Z","date":"2025-11-17","kind":"purchase","planned":false,"acquired":true,"shares":3500,"price":8.43,"value":29505.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares purchased in open-market transactions."}],"balance_after":13500,"source":{"system":"sec-edgar","filing":"0001437749-25-035655","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1053691/000143774925035655/rdgdoc.xml","form_type":"4"}},{"id":998164,"issuer":{"id":7338,"kind":"organization","name":"CervoMed Inc."},"owners":[{"id":66563,"kind":"person","name":"Winton Matthew","position":1,"cik":"0001971400","reported_name":"Winton Matthew","relationship":{"officer":true,"officer_title":"Chief Commercial and Business"}}],"security":"Common Stock","published_at":"2025-11-17T14:01:17.000Z","date":"2025-11-14","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":7.57,"value":75700.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares purchased in open-market transactions."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. The shares were purchased in open-market transactions at prices ranging from $7.53 to $7.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full detail regarding the number of shares purchased at each separate price within such range."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001437749-25-035308","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1053691/000143774925035308/rdgdoc.xml","form_type":"4"}},{"id":1021696,"issuer":{"id":7338,"kind":"organization","name":"CervoMed Inc."},"owners":[{"id":66563,"kind":"person","name":"Winton Matthew","position":1,"cik":"0001971400","reported_name":"Winton Matthew","relationship":{"officer":true,"officer_title":"Chief Commercial and Business"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-08T20:07:23.000Z","date":"2025-10-06","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares granted as an inducement award material to Dr. Winton's entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). Award vests in equal monthly installments over thirty-six (36) months on the last day of each month commencing October 31, 2025."}],"balance_after":75000,"derivative":{"exercise_price":8.62,"expiration_date":"2035-10-06","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001437749-25-030707","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1053691/000143774925030707/rdgdoc.xml","form_type":"4"}},{"id":1092802,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":66563,"kind":"person","name":"Winton Matthew","position":1,"cik":"0001971400","reported_name":"Winton Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-03T19:08:49.000Z","date":"2025-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":145000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 16, 2025, by and among the Issuer, BioMarin Pharmaceutical Inc., a Delaware corporation (\"Parent\"), and Incline Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the \"Company Common Stock\"), for a price per share of $4.00 (the \"Merger Consideration\"), without interest and subject to any withholding of taxes required by applicable law. Effective as of July 1, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly-owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock (\"Company Option\"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration was automatically accelerated and became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock (\"Company Option\"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration was automatically accelerated and became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option."}],"balance_after":0,"derivative":{"exercise_price":1.06,"expiration_date":"2035-03-10","underlying":"Common Stock","underlying_shares":145000},"source":{"system":"sec-edgar","filing":"0000950170-25-094098","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1971400/000095017025094098/ownership.xml","form_type":"4"}},{"id":1092801,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":66563,"kind":"person","name":"Winton Matthew","position":1,"cik":"0001971400","reported_name":"Winton Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Restricted Stock Units","published_at":"2025-07-03T19:08:49.000Z","date":"2025-07-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":41500,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a \"Company RSU Award\"), whether vested or unvested that was outstanding immediately prior to the Effective Time, was automatically accelerated, became fully vested, and was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration."},{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 16, 2025, by and among the Issuer, BioMarin Pharmaceutical Inc., a Delaware corporation (\"Parent\"), and Incline Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the \"Company Common Stock\"), for a price per share of $4.00 (the \"Merger Consideration\"), without interest and subject to any withholding of taxes required by applicable law. Effective as of July 1, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly-owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a \"Company RSU Award\"), whether vested or unvested that was outstanding immediately prior to the Effective Time, was automatically accelerated, became fully vested, and was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a \"Company RSU Award\"), whether vested or unvested that was outstanding immediately prior to the Effective Time, was automatically accelerated, became fully vested, and was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a \"Company RSU Award\"), whether vested or unvested that was outstanding immediately prior to the Effective Time, was automatically accelerated, became fully vested, and was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":41500},"source":{"system":"sec-edgar","filing":"0000950170-25-094098","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1971400/000095017025094098/ownership.xml","form_type":"4"}},{"id":1092800,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":66563,"kind":"person","name":"Winton Matthew","position":1,"cik":"0001971400","reported_name":"Winton Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Common Stock","published_at":"2025-07-03T19:08:49.000Z","date":"2025-07-01","kind":"other","planned":false,"acquired":false,"shares":21743,"price":4,"value":86972.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 16, 2025, by and among the Issuer, BioMarin Pharmaceutical Inc., a Delaware corporation (\"Parent\"), and Incline Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the \"Company Common Stock\"), for a price per share of $4.00 (the \"Merger Consideration\"), without interest and subject to any withholding of taxes required by applicable law. Effective as of July 1, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly-owned subsidiary of Parent (the \"Merger\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each share of Company Common Stock held by the Reporting Person was tendered in exchange for the Merger Consideration, without interest and subject to any withholding of taxes required by applicable law."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-25-094098","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1971400/000095017025094098/ownership.xml","form_type":"4"}},{"id":1100467,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":66563,"kind":"person","name":"Winton Matthew","position":1,"cik":"0001971400","reported_name":"Winton Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Common Stock","published_at":"2025-06-27T16:05:19.000Z","date":"2025-06-25","kind":"grant","planned":false,"acquired":true,"shares":14355,"price":0.74,"value":10622.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares purchased pursuant to the Inozyme Pharma, Inc. 2020 Employee Stock Purchase Plan (\"ESPP\"), for the ESPP purchase period of April 1, 2025 through June 25, 2025. In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on April 1, 2025, the first trading day of the purchase period."}],"balance_after":21743,"source":{"system":"sec-edgar","filing":"0000950170-25-090868","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1971400/000095017025090868/ownership.xml","form_type":"4"}},{"id":1183983,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":66563,"kind":"person","name":"Winton Matthew","position":1,"cik":"0001971400","reported_name":"Winton Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Common Stock","published_at":"2025-04-02T16:29:22.000Z","date":"2025-03-31","kind":"grant","planned":false,"acquired":true,"shares":2490,"price":0.77,"value":1917.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares purchased pursuant to the Inozyme Pharma, Inc. 2020 Employee Stock Purchase Plan (\"ESPP\"), for the ESPP purchase period of October 1, 2024 through March 31, 2025. In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on March 31, 2025, the last trading day of the purchase period."}],"balance_after":7388,"source":{"system":"sec-edgar","filing":"0000950170-25-049393","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1971400/000095017025049393/ownership.xml","form_type":"4"}},{"id":1204183,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":66563,"kind":"person","name":"Winton Matthew","position":1,"cik":"0001971400","reported_name":"Winton Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Restricted Stock Units","published_at":"2025-03-17T16:25:34.000Z","date":"2025-03-11","kind":"grant","planned":false,"acquired":true,"shares":41500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The restricted stock units were granted on March 11, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. 33% of the restricted stock units vest on March 11, 2026, with the remaining 67% vesting in eight equal quarterly installments thereafter, such that the restricted stock units will be fully vested on March 11, 2028."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units were granted on March 11, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. 33% of the restricted stock units vest on March 11, 2026, with the remaining 67% vesting in eight equal quarterly installments thereafter, such that the restricted stock units will be fully vested on March 11, 2028."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units were granted on March 11, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. 33% of the restricted stock units vest on March 11, 2026, with the remaining 67% vesting in eight equal quarterly installments thereafter, such that the restricted stock units will be fully vested on March 11, 2028."}],"balance_after":41500,"derivative":{"underlying":"Common Stock","underlying_shares":41500},"source":{"system":"sec-edgar","filing":"0000950170-25-040318","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1971400/000095017025040318/ownership.xml","form_type":"4"}},{"id":1204182,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":66563,"kind":"person","name":"Winton Matthew","position":1,"cik":"0001971400","reported_name":"Winton Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Stock Option (right to buy)","published_at":"2025-03-17T16:25:34.000Z","date":"2025-03-11","kind":"grant","planned":false,"acquired":true,"shares":145000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price represents the closing price of the Issuer's common stock on March 11, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was granted on March 11, 2025 and is scheduled to vest in equal monthly installments until the fourth anniversary of the grant date."}],"balance_after":145000,"derivative":{"exercise_price":1.06,"expiration_date":"2035-03-10","underlying":"Common Stock","underlying_shares":145000},"source":{"system":"sec-edgar","filing":"0000950170-25-040318","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1971400/000095017025040318/ownership.xml","form_type":"4"}},{"id":1392366,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":66563,"kind":"person","name":"Winton Matthew","position":1,"cik":"0001971400","reported_name":"Winton Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Common Stock","published_at":"2024-10-03T20:57:02.000Z","date":"2024-09-30","kind":"grant","planned":false,"acquired":true,"shares":1710,"price":4.45,"value":7609.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares purchased pursuant to the Inozyme Pharma, Inc. 2020 Employee Stock Purchase Plan (\"ESPP\"), for the ESPP purchase period of April 1, 2024 through September 30, 2024. In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on September 30, 2024, the last trading day of the purchase period."}],"balance_after":4898,"source":{"system":"sec-edgar","filing":"0000950170-24-112694","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1971400/000095017024112694/ownership.xml","form_type":"4"}},{"id":1550448,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":66563,"kind":"person","name":"Winton Matthew","position":1,"cik":"0001971400","reported_name":"Winton Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Common Stock","published_at":"2024-04-03T17:23:00.000Z","date":"2024-03-28","kind":"grant","planned":false,"acquired":true,"shares":3188,"price":3.33,"value":10616.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares purchased pursuant to the Inozyme Pharma, Inc. 2020 Employee Stock Purchase Plan (\"ESPP\"), for the ESPP purchase period of October 1, 2023 through March 31, 2024. In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on October 2, 2023, the first trading day of the purchase period."}],"balance_after":3188,"source":{"system":"sec-edgar","filing":"0000950170-24-041300","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1971400/000095017024041300/ownership.xml","form_type":"4"}},{"id":1575012,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":66563,"kind":"person","name":"Winton Matthew","position":1,"cik":"0001971400","reported_name":"Winton Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Stock Option (right to buy)","published_at":"2024-03-15T08:30:09.000Z","date":"2024-03-13","kind":"grant","planned":false,"acquired":true,"shares":175000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on March 13, 2024 and is scheduled to vest in equal monthly installments until the fourth anniversary of the grant date."}],"balance_after":175000,"derivative":{"exercise_price":5.77,"expiration_date":"2034-03-12","underlying":"Common Stock","underlying_shares":175000},"source":{"system":"sec-edgar","filing":"0000950170-24-031878","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1971400/000095017024031878/ownership.xml","form_type":"4"}},{"id":1929138,"issuer":{"id":77717,"kind":"organization","name":"Inozyme Pharma, Inc.","symbol":"INZY"},"owners":[{"id":66563,"kind":"person","name":"Winton Matthew","position":1,"cik":"0001971400","reported_name":"Winton Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO"}}],"security":"Stock option (right to buy)","published_at":"2023-04-04T08:35:20.000Z","date":"2023-04-03","kind":"grant","planned":false,"acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on April 3, 2023 and is scheduled to vest 25% on the first anniversary of the grant date. The remainder of the shares underlying the option are scheduled to vest in equal monthly installments over the following three years until the fourth anniversary of the grant date."}],"balance_after":250000,"derivative":{"exercise_price":5.39,"expiration_date":"2033-04-02","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001209191-23-022465","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1971400/000120919123022465/doc4.xml","form_type":"4"}}]}